(ChemotherapyAdvisor) – First-line treatment with sunitinib for 9 months or more may be associated with a longer progression-free survival (PFS) in patients who receive subsequent VEGFR tyrosine kinase inhibitors, results of Phase 3 AXIS trial data in second-line metastatic renal cell carcinoma (RCC) comparing axitinib and sorafenib presented during the 2012 Genitourinary Cancers Symposium have found.
Brian I. Rini, MD, of the Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, and colleagues evaluated the effect of prior sunitinib treatment duration and axitinib dose titration on subsequent axitinib efficacy within the AXIS trial, in which axitinib significantly prolonged median PFS, 6.7 vs 4.7 months (HR=0.665; P<0.0001).
A total of 53.7% of patients (n=194) in the axitinib arm and 53.9% in the sorafenib arm (n=195) received prior treatment with sunitinib. Median PFS for prior sunitinib treatment duration ≥6 months and <6 months was 4.8 vs. 4.6 months for axitinib and 4.6 vs. 2.9 months for sorafenib. For duration of prior sunitinib ≥9 months and <9 months, median PFS was 6.3 vs. 4.5 months for axitinib and 4.6 vs 2.9 months for sorafenib. Median PFS for patients receiving at least one total daily axitinib dose >10 mg (dose-titrated group; n=132) was 6.6 months vs. 8.3 months for those receiving axitinib ≤10 mg (n=227).
The FDA approved axitinib (Inlyta), Pfizer Inc, for the treatment of advanced RCC after failure of one prior systemic therapy on January 27, 2012.
The 2012 Genitourinary Cancers Symposium is sponsored by the American Society of Clinical Oncology, American Society for Radiation Oncology, and the Society of Urologic Oncology.